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ABSTRACT
Adult mesenchymal stem cells possess a remarkably diverse array of immunosuppressive characteristics. The capacity to suppress the regular
processes of allogeneic rejection, have allowed the use of tissue mismatched cells as therapeutic approaches in regenerative medicine and as
agents of immune deviation. This review describes recent advances in understanding the mechanistic basis of mesenchymal stromal or stem
cells (MSC) interaction with innate immunity. Particular emphasis is placed on the effect of Toll-like receptor signalling on MSC and a
hypothesis that innate immune signals induce a ‘licensing switch’ in MSC is put forward. The mechanisms underlying MSC suppression of T
cell responses and induction of regulatory populations are surveyed. Conflicting data regarding the influence of MSC on B cell function are
outlined and discussed. Finally the limits to MSC mediated immune modulation are discussed with reference to the future clinical application
of novel cell therapies. J. Cell. Biochem. 112: 1963–1968, 2011.  2011 Wiley-Liss, Inc.
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C ell-based therapies to treat human disease are set to becomeclinical reality. To the fore of these novel approaches is the
use of adult mesenchymal stromal or stem cells (MSC). The term
‘mesenchymal stem cell’ was coined by Caplan in 1991 [Caplan,
1991] to describe the rare population of bone marrow derived,
plastic adherent cells discovered by Friedenstein and Petrokova
[1966]. Originally these stromal cells were assumed to directly repair
degenerative disease by differentiation; however, it is now
appreciated that MSC also release soluble factors that act in a
paracrine manner to promote repair [Caplan, 2009]. However, while
MSC might be considered as trophic agents that guide the processes
of tissue repair, the nature of the trophic activities remain ill defined.
The beneficial actions of MSC encompass anti-apoptotic,
cytoprotective effects and the promotion of angiogenesis [Caplan,
2009] and it is the multifactorial, coordinated and targeted features
of MSC that make the cell therapy approach superior to small
molecule modalities. Angiogenic action is likely to be an important
component of tissue repair; pericyte mediated vascular stability
contributes to wound healing and tissue resident MSC may be
derived from a perivascular precursor [Bianco et al., 2010], and may
be intimately involved in neovascularisation of wounds and
therefore regeneration.
Whilst the above features are important attributes of MSC
biology, one trophic function has become the subject of intense
scrutiny in the last 7 years. It is now apparent that MSC are powerful
modulators of the mammalian immune response. These findings
date back to studies which demonstrated that tissue mismatched
(allogeneic) and even species mismatched (xenogeneic) MSC were
effective cell therapies [Bartholomew et al., 2002; Grinnemo et al.,
2004]. The implications were that MSC would disobey the regular
rules of tissue transplantation and enjoy a degree of immune
privilege, such that cell therapy could be based on allogeneic cells
rather than autologous cell transplantation. This belief has
important consequences as it means that MSC could be used as a
commercially viable product, that was amenable to scale up and
standardisation. It also implied that allogeneic MSC could be used as
agents of immune deviation in conditions such as graft versus host
disease (GvHD), type I diabetes or autoimmune diseases, in addition
to regenerative applications for myocardial infarction or joint
damage.
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The intervening years have seen a rapid delineation of the
mechanisms by which MSC modulate different aspects of both the
innate and adaptive immune response. This has been accompanied
by a large number of clinical trials in which allogeneic MSC have
been safely deployed against a wide range of human diseases. This
article will outline the immunological processes modulated by MSC,
propose a model that attempts to resolve some conflicting data
especially in innate immune modulation, discuss the implications
for cell therapy, and finally survey those aspects of MSC biology that
require further study.
MSC SUPPRESSION OF INNATE IMMUNITY
The innate immune system is a complex, rapid and effective barrier
to microbes but is also a series of interlinked responses that can
confound transplantation and cell therapy. These responses may be
cell based, or involve serum components such as the complement
system. Allogeneic human MSC and indeed some xenogeneic MSC
typically avoid acute and hyperacute rejection mechanisms
normally mediated through complement. Protection from this
deletional process is afforded by MSC expression of factor H [Tu
et al., 2010] and other complement control proteins. However, whilst
MSC are protected from complement killing they are not inert to
other complement mediated activities. MSC can be recruited by the
complement anaphylatoxins C3a and C5a [Schraufstatter et al.,
2009], suggesting that signals initiated at sites of tissue damage
recruit MSC protected from regular innate deletion. Protection also
extends to cell mediated innate mechanisms as well; human MSC
suppress the proliferation, surface receptor expression and effector
functions of NK cells via prostaglandins and indoleamine
dioxygenase (IDO); however, this protection is limited as MSC
may be lysed under some circumstances by activated NK cells
[Spaggiari et al., 2008] (Fig. 1).
An emerging concept is that MSC are not only protected from
innate immune functions, but may contribute to shaping the
processes of inflammation and repair. Therefore MSC are properly
considered in the context of inflammatory responses. Monocytes
and macrophages are frontline immune effector cells capable of
destructive and lytic effects at sites of microbial insult, but can
produce a range of regenerative factors involved in repair. Recent
data suggest MSC may assist in coordination of these processes
[Ohtaki et al., 2008; Nemeth et al., 2009]. Likewise, MSC block
neutrophil function by suppressing the oxidative burst of resting
and activated neutrophils while preserving their phagocytic and
chemotactic functions [Raffaghello et al., 2008]. Furthermore, recent
in vivo data suggest that MSC also suppress inflammatory
eosinophil localisation in vivo [Kavanagh and Mahon, 2011]. Thus
MSC appear to be recruited by, but protected from, the principle
innate deletional mechanisms and suppress a range of inflammatory
pathways consistent with functions in co-ordinating the resolution
of inflammation and a transition to reparative processes.
Thus there is a conceptual dilemma in modelling MSC interaction
with the innate immune response. MSC need to be recruited to sites
Fig. 1. Summary ofMSC-immune interactions. MSCmodulate innate and adaptive immunity through cell contact and soluble factors such as prostaglandins (PG), interleukins
(IL)-6 and 10, Transforming growth factor (TGF)-b, and expression of the enzyme indoleamine 2,3,dioxygenase (IDO) resulting in immune suppression (blunt lines). MSC also
suppress immunity by modulating DC maturation and inducing regulatory T cells (arrows). Although MSC can suppress B cell responses either directly or via CD4þ Th
suppression, activation of B cells and antibody (Ig) stimulation can occur in some situations.
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of physiological insult, contribute to repair, and the resolution of
inflammation, but not interfere with the processes of immune
protection against pathogens. In this regard the differential
expression of Toll-like receptors (TLR) and the control of expression
has assumed a central importance [Pevsner-Fischer et al., 2007;
Liotta et al., 2008; Tomchuck et al., 2008]. MSC express a range of
TLR, and signalling via these receptors influences migration,
survival, differentiation and immunosuppressive capacity. MSC
immune modulation may be down-regulated by TLR3 and TLR4
ligands [Liotta et al., 2008; Romieu-Mourez et al., 2009] but
enhanced by IFN-g [English et al., 2007]. However, TLR ligation
alters the induction of cytokines and other inflammatory mediators
and under some conditions, further enhances MSC mediated
immune suppression [Tomchuck et al., 2008]. These findings
suggest a model where inflammation in the absence of pathogen
associated molecular pattern (PAMP) molecules stimulates or
‘licences’ MSC to promote regular (non-fibrotic) repair and dampen
inflammation (Fig. 2). In contrast, in the presence of PAMPS and
robust TLR signalling (e.g., tissue damage where pathogens are yet to
be cleared) MSC are less suppressive of inflammation and adopt a
more fibrotic character. If this hypothesis proves correct, MSC may
be particularly effective in suppressing chronic inflammation
associated with autoimmunity without impairing inflammatory
responses essential to antimicrobial defence.
MSC MODULATION OF DENDRITIC CELL FUNCTION
Dendritic cells (DC) are sentinel cells critical for the initiation of
antigen specific helper T cells. Host or graft derived DC can
contribute to graft rejection through either the direct or indirect
pathways of allorecognition, and MSC modulate DC development
and function in multiple ways [Nauta et al., 2006; Djouad et al.,
2007]. For example MSC appear to have differential effects on the
generation of conventional DC and plasmacytoid DC [Chen et al.,
2007]. Most importantly, MSC modulate conventional DC matura-
tion to induce a tolerogenic DC population. This involves down
modulation of DC expressions of MHC class II, the co-stimulatory
molecules CD40, CD80 and CD86, and prevention of the lymph node
homing chemokine receptor CCR7 [Djouad et al., 2007; English
et al., 2008; Li et al., 2008; Zhang et al., 2009]. Conversely allogeneic
MSC preserve DC expression of E-cadherin in vitro [English et al.,
2008], implying that MSC suppress lymph node homing (a pre-
requisite for T cell response initiation) and anchor the DC in the
peripheral tissues, a hypothesis that awaits testing in vivo. What is
clear is that MSC suppress DC antigen presentation, surface marker
switch, and homing capacity—the three cardinal signs of matura-
tion.
MSC also ‘re-programme’ the conventional myeloid DC response
to activating stimuli, converting pro-inflammatory responses (IL-
12, TNF-a) to anti-inflammatory cytokine production (IL-10)
[Zhang et al., 2009]. Functionally, DC that have encountered
MSC suppress the proliferation of activated T cells [Zhang et al.,
2009], influence the ratio of T cell subsets, and promote regulatory T
cells (Treg) [Li et al., 2008; Ge et al., 2009]. Once again it is likely that
different in vivo microenvironments and the specific conditions
encountered will influence the precise effect that MSC have on DC,
these variables are compounded by the heterogeneity of DC
populations used in such studies and these considerations may
explain the heterogeneity of data reported to date. Nevertheless,
Fig. 2. A hypothetical MSC switch. Inflammatory signals are essential to recruit MSC to sites of tissue damage, causing the stimulation or ‘licensing’ of enhanced function.
This may be influenced by the presence of pathogen associated molecular pattern molecules (PAMP) acting as a switch to activate Toll-like receptor (TLR) signalling. Under
inflammatory conditions in the absence of PAMP, MSC are licensed for anti-inflammatory, anti-fibrotic and reparative functions; however when TLR are engaged (such as during
active microbe driven pathology), a more fibrotic response is initiated, and MSC are less suppressive of inflammation.
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MSC clearly preserve DC immaturity, reduce the capacity for
inflammatory responses and limit the capacity of DC to initiate T cell
responses.
MSC SUPPRESSION OF ADAPTIVE IMMUNITY
The ability of MSC to suppress alloantigen driven proliferation in
mixed lymphocyte reactions was an early indication that these cells
disobey the conventional paradigm regarding adaptive immunity to
non-matched cells [Bartholomew et al., 2002]. This is in part
attributable to MSC production of prostaglandins [English et al.,
2007; Ryan et al., 2007]. However, the capacity of MSC to modulate
T cell responses is also dependent on the inflammatory micro-
environment in which MSC and T cells interact [Polchert et al.,
2008]. Unexpectedly, IFN-g does not break but rather enhances the
capacity of MSC to suppress T cell proliferation through induction of
IDO and other factors [English et al., 2007; Ryan et al., 2007; Ren
et al., 2008]. Indeed some studies suggest that there is a requirement
for IFN-g, and/or IL-1b in the activation of MSC immune
suppressive functions [Ren et al., 2008], a finding that parallels
repair in non-mammalian systems where inflammation is a pre-
requisite for regeneration [Young, 2004].
The differentiation of CD4þ T cells to specific subsets is also
influenced by MSC; with the mesenchymal cell skewing T cell
responses towards regulatory patterns of cytokine secretion and
concurrent suppression of Th1, Th2 or Th17 responses [Nemeth
et al., 2009; Rafei et al., 2009; Ghannam et al., 2010]. These data are
supported by elegant in vivo models of transplantation and
autoimmune disease where MSC alter T cell polarisation away
from the typical effector responses [Casiraghi et al., 2008; Ge et al.,
2009; Rafei et al., 2009; Kavanagh and Mahon, 2011]. Treg
themselves are candidate cell therapeutics but the ability of MSC to
induce these cells and also mediate repair suggests cell therapy
directed at the induction of tolerance in organ transplantation,
GvHD, and autoimmune disorders. It is well established that Treg
control alloreactive T cell responses [Nadig et al., 2010] and that
MSC can directly induce CD4þCD25þ FoxP3þ Treg [English et al.,
2009]. MSC-induced Treg have been shown to be donor specific in a
mouse model of cardiac allograft rejection [Casiraghi et al., 2008],
and human Treg induced by MSC can be isolated and suppress
allogeneic responses even when MSC are no longer present [English
et al., 2009]. Thus MSC suppression via Treg appears to operate by
both infectious tolerance and bystander suppressive mechanisms
[Griffin et al., 2010].
The signals involved in MSC induction of Treg have been
investigated by a number of groups. While cell contact in
combination with PGE2 and TGF-b are key factors [English
et al., 2009]; MSC secretion of HLA-G, IL-10 and LIF can also drive
Treg expansion [Selmani et al., 2008]. The induction of Treg by
allogeneic MSC has functional relevance in vivo, in a murine model
of allergic asthma the beneficial therapeutic effect of MSC therapy is
lost when Treg are depleted [Kavanagh and Mahon, 2011].
MSC-mediated immunomodulation occurs bymultiple redundant
pathways, and the induction of CD4þ Treg is paralleled by other
modulatory mechanisms. CD8þ regulatory cells can be induced by
MSC, and MSC can inhibit effector CD8þ cytotoxic T lymphocyte
(CTL) proliferation [Rasmusson et al., 2003; Ramasamy et al., 2008].
MSC were not lysed by CD8þ T cells [Rasmusson et al., 2003], and
soluble HLA-G played a partial protective role [Morandi et al., 2008].
However, there is heterogeneity in the findings with regard to the
effect of MSC on CTL killing of target cells. Rasmusson et al. [2003]
showed that inhibition of CTL mediated lysis in mixed lymphocyte
cultures was only effective when MSC were present at the beginning
of a 6-day culture whereas addition of MSC at day 3 or in the effector
cytotoxic phase had no effect on CTL function. Similarly, Ramasamy
et al. [2008] found that MSC did not inhibit CTL mediated lysis of
target cells in short-term assay systems. While it is difficult to
compare data across different experimental systems these findings
may indicate that MSC are more suppressive of CTL proliferation
and/or induction (of antigen-specific responses) than the effector or
lytic processes. This interpretation is consistent with the finding that
MSC therapy does not interfere with virus-specific T cell responses
[Karlsson et al., 2008].
Studies of the influence of MSC on B cell function have also
generated heterogeneous results [Corcione et al., 2006; Rasmusson
et al., 2007; Rafei et al., 2008; Traggiai et al., 2008; Asari et al.,
2009]. Co-culture of human MSC with purified B cell populations
under stimulatory conditions may inhibit B cell activation
(proliferation differentiation, immunoglobulin (Ig) production and
chemotaxis) [Corcione et al., 2006]. This suppression may be
mediated by alternatively cleaved CCL2 [Rafei et al., 2008], and the
PD1/PDL1 interaction [Schena et al., 2010]. In contrast, there are
consistent reports of MSC mediated stimulatory effects on in vitro-
activated B cells or plasma cells from healthy humans [Rasmusson
et al., 2007] and in patients with systemic lupus erythematosis (SLE)
[Traggiai et al., 2008]. The reasons for such apparently contradictory
results cannot be fully assigned to variability in the sources of MSC,
or the different antigen-dependent or polyclonal stimuli used. There
appears to be a genuine, if limited, MSC mediated stimulatory
phenomenon in vivo. The recent appreciation of CD4þ T follicular
helper cells and new techniques to track individual MSC to lymph
nodes in vivo [Steyer et al., 2009] may give some clues to the
biological phenomena operating in the B cell compartment in the
near future. Intriguingly it is possible that MSC are inducing the
phenomenon of split tolerance with differential effects on the T cell
and B cell compartments [Nash and Ashford, 1982], and systems
where T cell-independent B cell responses are studied may resolve
these issues.
DEFINING THE LIMITS OF MSC MEDIATED
SUPPRESSION
Allogeneic MSC have now been used therapeutically and safely in a
large number of human clinical trials [Griffin et al., 2010]. These
diverse studies can be informative in revealing whether the immune
suppressive properties of MSC are sufficient to overcome the diverse
processes of immune priming, and effector responses provoked by
allogeneic cells. Pre-clinical and clinical studies provide evidence
for a therapeutic benefit of allogeneic MSC, however, whether MSC
enjoy complete immune privilege in vivo seems less clear and this
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may impact on the clinical targets, and commercial benefits of MSC
therapies in the long-term. For example, the immunogenicity of
MSC following differentiation to chondrocytes, osteocytes or other
lineages is poorly characterised, and may be of importance for cell
therapy for myocardial, bone or joint diseases. In a rabbit model,
allogeneic MSC-derived osteogenic cells retained immunosuppres-
sive properties in vitro and functioned as osteoblasts in vivo without
sensitising to a subsequent MSC-donor-specific skin graft [Liu et al.,
2006]; however, recent data suggest that allogeneic MSC are
immunogenic on differentiation and this limits their benefit [Huang
et al., 2010]. It is also unclear whether current immunosuppressive
modalities for organ transplantation influence the therapeutic
effects of allogeneic MSC in vivo. The calcineurin inhibitor
tacrolimus reduces anti-donor antibody responses to allogeneic
MSC in a pig model [Poncelet et al., 2007]. Likewise, low-dose
sirolimus combined with allogeneic MSC therapy resulted in long-
term survival of MHC-mismatched heart transplants in mice [Ge
et al., 2009], suggesting cell therapy will not confound conventional
approaches. In many diseases, it is not known how long (or indeed
where) MSC need to persist in vivo in order to exert their beneficial
effects. For clinical applications that require permanent MSC
engraftment, even weak immunogenicity may confound successful
translation [Huang et al., 2010]. However, in conditions where
allogeneic MSC are used as agents of immune deviation to counter
an acute inflammatory condition or to ‘re-program’ autoimmunity,
then persistence may be less important and the suppressive features
of MSC may be sufficient to allow standardised allogeneic cell
therapy.
CONCLUDING REMARKS
The last decade has seen a remarkable shift in our appreciation of
the potential uses for MSC. First MSC were recognised as having
immunosuppressive properties, then the trophic (as opposed to
regenerative) effects became clear. These advances were followed by a
rapid delineation of the multiple pathways by which MSC modulate
immunity and somewhat unrealistic ambitions that MSC were an
immunological panacea. The field is now defining the limits of cell
therapy and the correlates of efficacy. The verymany ongoing clinical
trials of allogeneic MSC and MSC like cells [Griffin et al., 2010]
suggest that cell therapy for currently intractable conditions is a
realistic prospect. However, a number of issues remain to be resolved
such as the hierarchy of the immune suppressive functions of MSC
and the degree of redundancy that exists among themany suppressive
processes that have been identified to date. The limits of immune
modulation by allogeneic MSC are becoming clear, and these limits
will influence the choice of targets for cell therapy and help shape the
next generation of genetically modified or enhanced allogeneic MSC.
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